02146-A: Development of a Novel Drug Delivery System to Prevent Vision Loss in Canine Cataract Patients
Grant Status: Open
Cataracts are the most common cause of treatable blindness in dogs. Surgery is the only way to restore normal vision and although every effort is made to remove as much lens material as possible during cataract surgery, it is inevitable that some lens cells are left behind within the eye. These lens cells will move and multiply, resulting in the most common complication to cataract surgery, posterior capsule opacification (PCO). PCO interferes with light transmission and results in secondary vision loss in 80-100% of canine cataract patients. Unfortunately, there is no consistently effective treatment for PCO. Studies performed in laboratory animals have found that use of a commonly prescribed drug, Cyclosporine, can decrease PCO formation. Dr. Chandler believes that Cyclosporine may provide a safe, cost-effective and reliable option to prevent PCO. Using a laboratory animal model system, Dr. Chandler will evaluate the effectiveness of a novel gel-based drug delivery polymer to release Cyclosporine at the correct dose and time needed to prevent PCO. Post-cataract surgery, eyes will be treated with the delivery device releasing Cyclosporine while other eyes will be treated with the delivery device and no Cyclosporine. Dr. Chandler expects that her novel drug delivery gel will be able to release Cyclosporine for at least one week at the correct dose to prevent PCO. If successful, future studies will focus on incorporating Cyclosporine drug delivery in canine clinical trials, potentially providing ophthalmologists a new method of restoring and maintaining excellent vision in dogs that have been blinded by cataracts.
None at this time.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.